Genomics Institute of the Novartis Research Foundation
Compounds and compositions as c-kit and PDGFR kinase inhibitors
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR and PDGFR kinases.
Novartis AG IRM LLC
A A A A A A A A A A A A A C A A A A A A A C A A A A A A A A A A A A A A A A A A
A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P C07D A61P A61P A61P A61P A61P A61P A61P C07D A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P A61P
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Xiaolin Juliet Timothy Jon Valentina Donatella Xiaodong Werner
Li Nabakka Ramsey Loren Molteni Chianelli Liu Breitenstein